
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
In a complex future that promises some of the most revolutionary treatments ever developed, marketing plans cannot be built early enough.
almost 26 years ago
Neurology's Broader Promise: An Exclusive Interview with Christopher Reevealmost 26 years ago
A Right to Dreamalmost 26 years ago
Woman With a Mission: Pfizer's Lisa Egbuonu-Davis





